The patient experience sits at the very core of modern medicine, yet for millions of children and adults living with attention-deficit/hyperactivity disorder (ADHD), the standard of care remains fundamentally misaligned with the realities of daily life. While clinicians have made significant strides in diagnosing and destigmatizing the condition, a critical gap persists: current pharmacological interventions often fail to provide symptom coverage for the entire active day. This mismatch does more than cause frustration; it imposes a heavy burden on patients, families, and caregivers, threatening both professional success and personal well-being.
The Rising Prevalence and the Diagnostic Shift
The landscape of ADHD in the United States has undergone a seismic shift over the last quarter-century. According to data from the Centers for Disease Control and Prevention (CDC), the prevalence of parent-reported ADHD diagnoses among children has more than doubled, climbing from approximately 5.5% in 1997 to 12% in 2024.
This surge is not necessarily an indicator of a new epidemic, but rather a reflection of a more sophisticated medical understanding. Experts attribute this rise primarily to better clinical recognition, a concerted effort to reduce the stigma surrounding the disorder, and the adoption of more definitive diagnostic criteria. As the medical community has become more adept at identifying ADHD in childhood, it has also become increasingly aware of the disorder’s longevity.
It is now widely recognized that ADHD does not simply vanish at the threshold of adulthood. Approximately 6% of U.S. adults are currently estimated to live with the condition, with more than half of these individuals receiving their initial diagnosis well into their adult years. Despite this, the clinical approach to management has remained relatively static, relying heavily on stimulant medications—predominantly methylphenidate- or amphetamine-based therapies. These stimulants account for over 90% of all ADHD prescriptions, yet they are increasingly failing to meet the evolving needs of the modern, 24/7 world.
A Chronology of Clinical Shortfalls
The historical development of ADHD medication has been largely dictated by the "school and work" model—a framework that assumes a patient’s primary need for focus exists strictly between the hours of 8 a.m. and 4 p.m.
The Era of Short-Acting Stimulants
In the early decades of ADHD treatment, the primary objective was immediate, short-term symptom suppression. Medications were designed to provide a "burst" of efficacy. While this helped with early morning tasks, it necessitated multiple doses throughout the day, which was plagued by issues of non-adherence, forgetfulness, and the stigma of carrying medication to school or the workplace.
The Rise of Extended-Release (ER) Formulations
The introduction of long-acting or extended-release medications was intended to be a panacea. By allowing for once-daily dosing, these drugs aimed to simplify the treatment regimen. However, as clinicians, we have observed that these medications often fall short of their promise. Most of these "all-day" options provide a duration of efficacy between 10 and 12 hours. If a patient takes their dose at 7 a.m., the medication’s concentration in the bloodstream begins a steep decline by 7 p.m.
This creates a "clinical cliff." Just as a child begins their homework or an adult attempts to engage in meaningful evening time with their family, the medication wears off, often triggering "rebound" symptoms. These include heightened irritability, dysphoria, dizziness, or a sudden, sharp inability to concentrate.
Redefining the "Active Day"
The fundamental flaw in current ADHD management is the outdated definition of what constitutes an "active day." For the seven million U.S. children and 15.5 million adults managing ADHD, the day does not end when the bell rings or the computer is shut off.
The Morning Struggle
For many, the first hurdle of the day is simply getting out the door. However, many current ADHD medications require one to two hours to reach their full clinical effect. This leaves patients vulnerable during the most chaotic, high-stress part of the morning. A treatment that requires a lengthy "ramp-up" period is effectively useless for the breakfast table and the morning commute.
The Afternoon and Evening Void
The "afternoon slump" is a well-documented phenomenon in ADHD management. When long-acting medication begins to wane, patients are often left to navigate sports practice, tutoring, extracurricular activities, and complex social interactions without the support they require. For adults, the evening is often when the most important life tasks occur—managing household finances, nurturing intimate relationships, and engaging in personal growth. If a medication is designed to stop working at 7 p.m., the patient is essentially being abandoned by their treatment plan at the very moment they need it most.
Supporting Data and Comorbidities
The necessity for improved, sustained-release treatment is underscored by the high rate of co-occurring conditions. Data shows that nearly 78% of children with ADHD have at least one co-occurring condition, such as anxiety, depression, or significant deficits in coping skills.
When a patient’s ADHD symptoms are not adequately managed through the evening, the strain of these comorbid conditions is exacerbated. A child struggling with emotional regulation is significantly more likely to experience a meltdown during the "rebound" phase of their medication. An adult struggling with low self-esteem may find their symptoms of anxiety spiking as their executive function declines in the evening hours.
Furthermore, the reliance on "booster doses" to bridge this gap is a flawed strategy. Midday boosters present significant logistical hurdles:
- Adherence: Children are frequently forgetful, and midday doses are easily missed.
- Diversion: Immediate-release formulations brought to school settings carry a high risk of being diverted, misused, or stolen.
- Financial Burden: The requirement for additional doses increases out-of-pocket costs for families already balancing the high price of mental health care.
Implications for Future Therapy
The next evolution in ADHD pharmacotherapy must pivot away from "work-hour" efficacy and toward "total-day" stability. As investigators and clinicians, we believe the focus must shift to three pillars of innovation:
1. Rapid Onset of Action
Future treatments should aim to achieve meaningful symptom control within 30 minutes of administration. The ability to "switch on" focus during the critical morning transition is as vital as the ability to maintain it through the evening.
2. Advanced Drug Delivery Science
The most promising developments lie in the science of drug delivery. We are seeing innovations that utilize multi-phase release systems. By combining an initial burst for morning efficacy with subsequent, delayed-release phases, these formulations can mimic a steady state of symptom control. Technologies such as prodrug formulations and continuous-release matrices are currently paving the way to ensure that medication levels in the blood do not "nosedive" prematurely.
3. Holistic Treatment Optimization
Clinicians must move toward a more personalized model of care. This means selecting therapies based not just on the diagnosis, but on the patient’s lifestyle requirements. Does the patient have a demanding night-shift job? Is the child involved in high-stakes extracurriculars? The medication must be chosen to fit the life, not the other way around.
Conclusion: Bridging the Gap
We must stop treating ADHD as a condition that only manifests during business hours. The "active day" is a holistic concept that encompasses the entire window of a patient’s waking hours. By demanding better, more consistent, and more rapid-acting therapies, the medical community can move beyond the current status quo of "partial coverage."
The goal is not simply to manage a symptom; it is to support the patient in their entirety. By aligning the duration and timing of medication with the reality of the patient’s daily existence, we can reduce the reliance on booster doses, mitigate the risk of withdrawal and rebound, and ultimately provide a foundation for better outcomes in school, work, and family life. The science is evolving; it is time for our expectations of ADHD treatment to evolve with it.
About the Authors
Matthew Brams, MD, is Chief Medical Officer and a Co-Founder of Cingulate Therapeutics. With over 35 years of clinical experience in adult and child psychiatry, he has been instrumental in the FDA approval of over 25 central nervous system drugs.
Raul R. Silva, MD, is a Co-Founder of Cingulate Therapeutics and a practicing child and adolescent psychiatrist. A former Vice Chairman of Child and Adolescent Psychiatry at the New York University School of Medicine, Dr. Silva has authored over 125 publications focused on the complexities of pediatric mental health.
